These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25742762)

  • 1. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).
    AbouEzzeddine OF; Haines P; Stevens S; Nativi-Nicolau J; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    JACC Heart Fail; 2015 Mar; 3(3):245-52. PubMed ID: 25742762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle.
    deFilippi CR; Christenson RH
    JACC Heart Fail; 2015 Mar; 3(3):253-6. PubMed ID: 25742763
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
    J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Demographic, and Imaging Correlates of Anemia in Heart Failure With Preserved Ejection Fraction (from the RELAX Trial).
    Parcha V; Patel N; Kalra R; Bhargava A; Prabhu SD; Arora G; Arora P
    Am J Cardiol; 2020 Jun; 125(12):1870-1878. PubMed ID: 32307089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Mohammed SF; Borlaug BA; McNulty S; Lewis GD; Lin G; Zakeri R; Semigran MJ; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jul; 7(4):580-9. PubMed ID: 24833648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of moderately reduced renal function on the diagnostic and prognostic value of galectin-3 in patients with exertional dyspnea.
    Karolko B; Serafin A; Przewłocka-Kosmala M
    Adv Clin Exp Med; 2022 Aug; 31(8):873-879. PubMed ID: 35467088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial.
    Gandhi PU; Gaggin HK; Redfield MM; Chen HH; Stevens SR; Anstrom KJ; Semigran MJ; Liu P; Januzzi JL
    JACC Heart Fail; 2016 Nov; 4(11):860-869. PubMed ID: 27744089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction.
    Beltrami M; Ruocco G; Dastidar AG; Franci B; Lucani B; Aloia E; Nuti R; Palazzuoli A
    Clin Chim Acta; 2016 Jun; 457():99-105. PubMed ID: 27067445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction.
    Alogna A; Koepp KE; Sabbah M; Espindola Netto JM; Jensen MD; Kirkland JL; Lam CSP; Obokata M; Petrie MC; Ridker PM; Sorimachi H; Tchkonia T; Voors A; Redfield MM; Borlaug BA
    JACC Heart Fail; 2023 Nov; 11(11):1549-1561. PubMed ID: 37565977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction.
    DuBrock HM; AbouEzzeddine OF; Redfield MM
    PLoS One; 2018; 13(8):e0201836. PubMed ID: 30114262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
    Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
    Heart Vessels; 2019 Apr; 34(4):597-606. PubMed ID: 30315496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
    Wang H; Anstrom K; Ilkayeva O; Muehlbauer MJ; Bain JR; McNulty S; Newgard CB; Kraus WE; Hernandez A; Felker GM; Redfield M; Shah SH
    JAMA Cardiol; 2017 Aug; 2(8):896-901. PubMed ID: 28492915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.
    Kitzman DW; Brubaker PH; Herrington DM; Morgan TM; Stewart KP; Hundley WG; Abdelhamed A; Haykowsky MJ
    J Am Coll Cardiol; 2013 Aug; 62(7):584-92. PubMed ID: 23665370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of Nondiastolic Factors to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Mysiak A; Karolko B; Marwick TH
    J Am Coll Cardiol; 2016 Feb; 67(6):659-670. PubMed ID: 26868691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.